After a pair of trial setbacks with a separate program from ArQule, Japan-based drugmaker Daiichi Sankyo has decided to jettison an alliance with the Woburn, MA-based drug developer on an early-stage compound known as ARQ 092.
In the face of declining demand for diagnostic tests, LabCorp is focusing on its testing unit, signing a lab services and biomarker study deal with Bristol-Myers Squibb.
ReSearch Pharmaceutical Services is teaming up with Japan's Asklep to kick off a joint venture targeting the country's growing biotech and medical device industries.
Sony and Olympus in Japan are putting off indefinitely their highly touted partnership to concoct new endoscopes and other medical devices. The delay stems from continued Chinese regulatory snafus.
Edison Pharmaceuticals shed its stealth mode and went public with a $545 million-plus collaboration deal with Japan's Dainippon Sumitomo that centers on its lead late-stage drug for rare diseases.
BioDelivery Sciences secured rights from Arcion Therapeutics to commercialize the company's first-of-its-kind topical gel to treat painful diabetic neuropathy.
As part of an ambitious effort to prep for a future pandemic, GlaxoSmithKline and Texas A&M are teaming up to build a $91 million flu vaccine manufacturing center in the Lone Star state that will rely on cell-culture lines rather than chicken eggs.
PrimeraDx, a 2012 Fierce 15 company, has hitched on with Quest Diagnostics to co-develop companion diagnostics, giving the company a major megaphone to attract Big Pharma deals.
DKSH, a pharma market-services contractor, has re-upped with Bayer Healthcare to help the drug giant expand its presence in Cambodia, agreeing to handle importation, regulatory clearance and distribution in the Asian nation.
France's Sanofi is expanding its contract manufacturing capabilities, teaming up with Transgene to spend $13 million on a new CMO platform.